Quest Diagnostics Inc DGX
We take great care to ensure that the data presented and summarized in this overview for QUEST DIAGNOSTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DGX
View all-
Vanguard Group Inc Valley Forge, PA14.3MShares$1.95 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$1.38 Billion0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.19MShares$986 Million0.15% of portfolio
-
State Street Corp Boston, MA5.18MShares$711 Million0.03% of portfolio
-
Jpmorgan Chase & CO New York, NY4.32MShares$592 Million0.04% of portfolio
-
Boston Partners Boston, MA3.04MShares$416 Million0.5% of portfolio
-
Geode Capital Management, LLC Boston, MA2.98MShares$409 Million0.03% of portfolio
-
Victory Capital Management Inc2.81MShares$385 Million0.26% of portfolio
-
Morgan Stanley New York, NY2.15MShares$294 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.9MShares$261 Million0.06% of portfolio
Latest Institutional Activity in DGX
Top Purchases
Top Sells
About DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Insider Transactions at DGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,143
-5.6%
|
$1,250,025
$175.57 P/Share
|
|
Oct 22
2025
|
Gary M Pfeiffer Director |
SELL
Open market or private sale
|
Direct |
1,482
-4.79%
|
$269,724
$182.4 P/Share
|
|
Oct 21
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.2%
|
$2,835
$189.08 P/Share
|
|
Oct 21
2025
|
Vicky B Gregg Director |
BUY
Grant, award, or other acquisition
|
Direct |
70
+0.38%
|
$13,230
$189.08 P/Share
|
|
Oct 21
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.18%
|
$2,835
$189.08 P/Share
|
|
Oct 21
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.3%
|
$8,694
$189.08 P/Share
|
|
Oct 21
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
68
+0.26%
|
$12,852
$189.08 P/Share
|
|
Oct 21
2025
|
Robert B Carter Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.22%
|
$1,134
$189.09 P/Share
|
|
Sep 26
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
227
-0.3%
|
$42,449
$187.94 P/Share
|
|
Sep 26
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
227
+0.59%
|
$23,381
$103.57 P/Share
|
|
Sep 24
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
175
-0.46%
|
$32,725
$187.02 P/Share
|
|
Sep 24
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
175
+0.45%
|
$18,025
$103.57 P/Share
|
|
Sep 23
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
28,288
-42.6%
|
$5,289,856
$187.12 P/Share
|
|
Sep 23
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
28,288
+29.87%
|
$2,913,664
$103.57 P/Share
|
|
Aug 21
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
1,975
-11.45%
|
$365,375
$185.0 P/Share
|
|
Aug 19
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
4,532
-20.81%
|
$829,356
$183.0 P/Share
|
|
Aug 19
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Exercise of conversion of derivative security
|
Direct |
4,532
+17.23%
|
$507,584
$112.17 P/Share
|
|
Aug 15
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
1,975
-10.28%
|
$355,500
$180.0 P/Share
|
|
Aug 13
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
123
-1.45%
|
$21,525
$175.91 P/Share
|
|
Aug 06
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
5,535
-11.85%
|
$968,625
$175.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 158K shares |
|---|---|
| Small Acquisition | 676 shares |
| Exercise of conversion of derivative security | 113K shares |
| Open market or private sale | 183K shares |
|---|---|
| Payment of exercise price or tax liability | 79.1K shares |